Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9UHL4
UPID:
DPP2_HUMAN
Alternative names:
Dipeptidyl aminopeptidase II; Dipeptidyl peptidase 7; Dipeptidyl peptidase II; Quiescent cell proline dipeptidase
Alternative UPACC:
Q9UHL4; A8K7U7; Q5VSF1; Q969X4
Background:
Dipeptidyl peptidase 2, known by alternative names such as Dipeptidyl aminopeptidase II, Dipeptidyl peptidase 7, and Quiescent cell proline dipeptidase, plays a crucial role in the degradation of some oligopeptides. Its unique enzymatic activity is essential for maintaining various biological processes.
Therapeutic significance:
Understanding the role of Dipeptidyl peptidase 2 could open doors to potential therapeutic strategies. Its enzymatic function suggests a pivotal role in cellular mechanisms, offering a promising target for drug discovery efforts aimed at treating related disorders.